ERBB2 status and outcome of endocrine treatment.
Miller
W R
WR
D000077384:Anastrozole; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D066246:ErbB Receptors / Q000187:drug effects; D005260:Female; D006801:Humans; D009570:Nitriles / Q000494:pharmacology / Q000627:therapeutic use*; D017698:Postmenopause; D011379:Prognosis; D013629:Tamoxifen / Q000494:pharmacology / Q000627:therapeutic use*; D014230:Triazoles / Q000494:pharmacology / Q000627:therapeutic use*
D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D009570:Nitriles; D014230:Triazoles; D013629:Tamoxifen; D000077384:Anastrozole; C512478:EGFR protein, human; D066246:ErbB Receptors